Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;15:5131–5146. doi: 10.2147/IJN.S257084

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Ou et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

A schematic diagram depicting the efficiency of miR-214 inhibitor delivery into cells by means of graphene oxide (GO)-polyethyleneimine (PEI). GO was conjugated with PEI polymers to form positively charged GO-PEI complexes. Negatively charged miR-214 inhibitor was wrapped into the GO-PEI complexes by electrostatic interactions. GP-inhibitor complexes were delivered into the cytoplasm through endocytosis and inhibited the expression of miR-214 in osteosarcoma cells. Due to miR-214 inhibited by GP-inhibitor, the expression of PTEN could be increased and demonstrated a therapeutic effect in vitro. The GP-inhibitor also showed good therapeutic effect on the subcutaneous xenograft tumor mouse model through intratumoral injection.